Advances in spectral unmixing have yielded direct clinical gains, particularly in identifying rare or dim immune populations such as PD-1 low tumor-infiltrating lymphocytes and CD56 bright NK cells [1,48,81,111]. Here, PDCD1 is linked to neoplasm.